We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.31%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$5.17B
AUM Growth
+$808M
(+19%)
Cap. Flow
+$417M
Cap. Flow
% of AUM
8.07%
Top 10 Holdings %
Top 10 Hldgs %
16.85%
Holding
722
New
51
Increased
415
Reduced
155
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$43.8M |
| 2 |
Gilead Sciences
GILD
|
+$40.8M |
| 3 |
GE Aerospace
GE
|
+$37.3M |
| 4 |
Motorola Solutions
MSI
|
+$24.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$23.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$53.2M |
| 2 |
Amgen
AMGN
|
+$30.4M |
| 3 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$21.5M |
| 4 |
Canadian National Railway
CNI
|
+$20.9M |
| 5 |
Becton Dickinson
BDX
|
+$18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.05% |
| 2 | Financials | 13.76% |
| 3 | Technology | 12.91% |
| 4 | Communication Services | 9.31% |
| 5 | Industrials | 8.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Edwards Lifesciences
EW
$47.6B
| $3.39M | 0.07% |
108,222
+40,734
| +60% | +$1.28M |
|
327
Ambarella
AMBA
$2.99B
| $3.39M | 0.07% |
61,962
+38,647
| +166% | +$2.09M |
|
328
CDW
CDW
$17.1B
| $3.38M | 0.07% |
+58,609
| New | +$3.3M |
|
329
Lumen
LUMN
$6.53B
| $3.37M | 0.07% |
143,105
+7,406
| +5% | +$181K |
|
330
CytomX Therapeutics
CTMX
$705M
| $3.37M | 0.07% |
195,000
+40,000
| +26% | +$526K |
|
|
SPLK
331
DELISTED
Splunk Inc
SPLK
| $3.33M | 0.06% |
53,467
+30,166
| +129% | +$1.81M |
|
332
Ovintiv
OVV
$17.5B
| $3.32M | 0.06% |
56,902
+10,898
| +24% | +$653K |
|
333
Vanda Pharmaceuticals
VNDA
$312M
| $3.32M | 0.06% |
237,000
| – | – |
|
|
FDC
334
DELISTED
First Data Corporation
FDC
| $3.31M | 0.06% |
+213,837
| New | +$3.36M |
|
|
IMMU
335
DELISTED
Immunomedics Inc
IMMU
| $3.3M | 0.06% |
+510,000
| New | +$2.58M |
|
|
EPZM
336
DELISTED
Epizyme, Inc
EPZM
| $3.29M | 0.06% |
192,000
-17,000
| -8% | -$226K |
|
|
BNY
337
Bank of New York Mellon
BNY
$108B
| $3.29M | 0.06% |
69,593
+11,030
| +19% | +$516K |
|
|
HOLI
338
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
| $3.27M | 0.06% |
192,819
+118,982
| +161% | +$2.09M |
|
339
Aflac
AFL
$63.9B
| $3.23M | 0.06% |
89,262
+7,788
| +10% | +$276K |
|
340
Veeco
VECO
$3.15B
| $3.23M | 0.06% |
108,283
+56,486
| +109% | +$1.57M |
|
341
Xencor
XNCR
$1.44B
| $3.23M | 0.06% |
135,000
+60,000
| +80% | +$1.45M |
|
|
PTLA
342
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.15M | 0.06% |
80,500
-4,500
| -5% | -$143K |
|
343
APA Corp
APA
$12.8B
| $3.15M | 0.06% |
61,233
-102,991
| -63% | -$5.79M |
|
|
ITCI
344
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.12M | 0.06% |
192,000
+75,000
| +64% | +$1.09M |
|
345
Southern Company
SO
$110B
| $3.11M | 0.06% |
62,420
+11,964
| +24% | +$591K |
|
|
EVHC
346
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $3.1M | 0.06% |
+50,550
| New | +$3.39M |
|
|
SCHW
347
Charles Schwab
SCHW
$177B
| $3.1M | 0.06% |
75,901
+17,179
| +29% | +$709K |
|
348
Truist Financial
TFC
$63.2B
| $3.09M | 0.06% |
69,196
+10,436
| +18% | +$488K |
|
349
American Electric Power
AEP
$73.7B
| $3.08M | 0.06% |
45,854
+6,717
| +17% | +$435K |
|
350
Dominion Energy
D
$62.5B
| $3.07M | 0.06% |
39,554
+8,053
| +26% | +$609K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q1 2017 Portfolio in Review
As of Q1 2017, Candriam SCA held 722 positions worth $5.17B, up 19% from $4.36B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Candriam SCA deployed $417M of net new capital in Q1 2017, opening 51 new positions and adding to 415 existing holdings. Its largest new stake was Copart: 1,499,296 shares worth $11.6M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $53.2M trimmed.
- Candriam SCA's largest Q1 2017 buy was Copart: 1,499,296 shares worth $11.6M.
- Candriam SCA added most to Celgene Corp in Q1 2017, an estimated $43.8M increase.
- Candriam SCA's biggest Q1 2017 reduction was Johnson & Johnson, cutting an estimated $53.2M.
- Candriam SCA fully exited TechnipFMC in Q1 2017, selling an estimated $7.64M.
- Candriam SCA's ten largest holdings make up 17% of its $5.17B portfolio in Q1 2017.
- Candriam SCA opened 51 new positions and closed 32 in Q1 2017.
- Candriam SCA's portfolio value rose 19% quarter-over-quarter to $5.17B.
Based on Candriam SCA's 13F filing for Q1 2017, filed 21 Apr 2017.